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PRECLINICAL RESEARCH
eneficial Effect of Hydroxyfasudil, a Specific
ho-Kinase Inhibitor, on Ischemia/Reperfusion
njury in Canine Coronary Microcirculation In Vivo
oyotaka Yada, MD, PHD,* Hiroaki Shimokawa, MD, PHD,† Osamu Hiramatsu, PHD,*
atsuya Kajita, MD, PHD,* Fumiyuki Shigeto, MD, PHD,* Etsuro Tanaka, MD, PHD,‡
oshiro Shinozaki, BS,§ Hidezo Mori, MD, PHD, Takahiko Kiyooka, MD,# Masashi Katsura, PHD,¶
eitaro Ohkuma, MD, PHD,¶ Masami Goto, MD, PHD,* Yasuo Ogasawara, PHD,*
umihiko Kajiya, MD, PHD#
urashiki, Fukuoka, Tokyo, Isehara, Suita, and Okayama, Japan
OBJECTIVES We examined whether hydroxyfasudil, a specific Rho-kinase inhibitor, exerts cardioprotective
effect on coronary ischemia/reperfusion (I/R) injury and, if so, whether nitric oxide (NO) is
involved.
BACKGROUND Recent studies have demonstrated that Rho-kinase is substantially involved in the pathogen-
esis of cardiovascular diseases; however, it remains to be examined whether it is also involved
in ischemia/reperfusion (I/R) injury.
METHODS Canine subepicardial small arteries (SA, 100 m) and arterioles (A, 100 m) were
observed by a charge-coupled device intravital microscope during I/R. Coronary vascular
responses to endothelium-dependent (acetylcholine, intracoronary [IC]) and -independent
(papaverine, IC) vasodilators were examined after I/R under the following four conditions:
control (n  7), NO synthase inhibitor alone (NG-monomethl-L-arginine [L-NMMA], IC,
n  4), hydroxyfasudil alone (IC, n  7), and hydroxyfasudil plus L-NMMA (n  7).
RESULTS Hydroxyfasudil significantly attenuated serotonin (IC)-induced vasoconstriction of SA (7
 1% vs. 2  1%, p  0.01). Coronary I/R significantly impaired coronary vasodilation to
acetylcholine after I/R (SA, p 0.05; and A, p 0.01 vs. before I/R) and L-NMMA further
reduced the vasodilation, whereas hydroxyfasudil completely preserved the responses. The
vasoconstriction by L-NMMA after I/R was significantly improved by hydroxyfasudil in
both-sized arteries (both p  0.01). Expression of endothelial nitric oxide synthase (eNOS)
protein in the ischemic endocardium of left anterior descending coronary artery area (as
determined by Western blotting) significantly decreased (79  4%) compared with the
nonischemic endocardium of LCX area (100  7%), which was improved by hydroxyfasudil
(105  6%, p  0.01). Hydroxyfasudil significantly reduced myocardial infarct size, and
hydroxyfasudil with L-NMMA also reduced the infarct size compared with L-NMMA
alone.
CONCLUSIONS Hydroxyfasudil exerts cardioprotective effects on coronary I/R injury in vivo, in which
NO-mediated mechanism may be involved through preservation of eNOS expres-
sion. (J Am Coll Cardiol 2005;45:599–607) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.10.053Cardiology Foundation
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tschemia-reperfusion (I/R) injury attenuates endothelium-
ependent dilation of large coronary arteries both in vitro
1,2) and in vivo (3,4). Endothelial dysfunction causes
dverse outcome in the coronary circulation (5). Reperfu-
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004, accepted October 18, 2004.ion injury is caused by direct myocardial injury through
oronary vasospasm, free radicals, and inflammatory re-
ponses (6,7). Furthermore, local coronary vasoconstrictions
n response to vasoconstrictors (e.g., serotonin) are en-
anced (8,9). However, the mechanism of I/R-induced
ascular injury remains to be clarified.
Recent studies have demonstrated that Rho-kinase, an
ffector of the small guanosine triphosphatase Rho, is
ubstantially involved in the pathogenesis of cardiovascular
iseases (10). Shimokawa et al. (10,11) have recently found
hat hydroxyfasudil is a potent and specific inhibitor of
ho-kinase and markedly inhibits coronary hyperconstric-
ion and macrophage migration. They also demonstrated
hat intracoronary serotonin induces coronary hypercontrac-
ions at the inflammatory coronary lesions both in vitro and
n vivo, in which up-regulated Rho-kinase is substantially
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Rho-Kinase and Reperfusion Injury February 15, 2005:599–607nvolved (12). Recent studies demonstrated that endothelial
xpression and activity of Rho-kinase are enhanced by
ypoxia, with a resultant down-regulation of endothelial
itric oxide synthase (eNOS) expression and reduced nitric
xide (NO) production (13), and that Rho-kinase is also
nvolved in a canine model of cerebral infarction associated
ith superoxide production and neutrophil infiltration (14).
It is conceivable that Rho-kinase is involved in the
echanisms of I/R injury associated with reduced endothe-
ial NO production. In this study, we thus examined
hether hydroxyfasudil exerts protective effect on coronary
/R injury in vivo and, if so, whether NO is involved.
ETHODS
nimal preparation. This study conformed to the Guide-
ine on Animal Experiments of Kawasaki Medical School
nd the Guide for the Care and Use of Laboratory Animals
ublished by the U.S. National Institutes of Health.
Mongrel dogs (15 to 25 kg, n 31) of either gender were
nesthetized with morphine (3 mg/kg, intramuscular) and
odium pentobarbital (25 mg/kg, intravenous). After intu-
ation, each animal was ventilated with a high-frequency jet
entilator (model VS600, IDC, Pittsburgh, Pennsylvania)
ith room air supplemented by 100% oxygen. Aortic
ressure and left ventricular pressure were continuously
onitored with an 8-F pigtail double manometer catheter
SPC-784A, Millar, Texas). The proximal portion of the
eft anterior descending coronary artery (LAD) was isolated
nd a transonic flow probe (T206, Transonic Systems,
thaca, New York) was placed around the vessel.
eedle-probe intravital microscope. The needle-probe
4.5 mm in diameter, VMS 1210, Nihon Kohden, Tokyo,
apan) contains a gradient index lens (with a magnification
f 200) surrounded by light guide fibers and a double lumen
heath. A doughnut-shaped balloon on the tip avoids direct
ompression of the vessels by the needle tip (15).
easurements of coronary diameters. We placed the
eedle probe gently on subepicardial microvessels. When a
lear vascular image was obtained, end-diastolic vascular
mages were taken with 30 pictures/s (15).
easurements of regional myocardial blood flow. Re-
ional myocardial blood flow was determined by the non-
adioactive microsphere (Sekisui Plastic Co, Ltd, Tokyo,
apan) technique, as previously described in detail (16).
riefly, 1 ml of the microspheres suspension (2 to 4  106
pheres) was injected into the left atrium 85 min after the
nset of coronary occlusion. Just before microsphere admin-
Abbreviations and Acronyms
I/R  ischemia-reperfusion
LAD left anterior descending coronary artery
LCX  left circumflex artery
NO  nitric oxidestration, a reference blood flow sample was drawn from theemoral artery at a constant rate of 8 ml/min for 2 min. The
-ray fluorescence of the stable heavy elements was mea-
ured by a wavelength-dispersive spectrometer (model PW
480, Phillips Co., Ltd., Eindhoven, the Netherlands) (16).
yocardial blood flow was calculated according to the
ormula: time flow  tissue counts  (reference flow/
eference counts) and was expressed in ml/g per minute
16).
estern blotting. Proteins were separated on sodium
odecyl sulfate (SDS)/polyacrylamide gel electrophoresis as
reviously described (17). The tissues were homogenized in
sample buffer (100 mM Tris-HCl [pH 6.8], 4% SDS,
.2% glycerol). The tissue lysate was centrifuged and the
upernatant collected. Protein concentration was quantified
y a bicinchoninate (BCA) protein assay kit (Pierce Chem-
cal, Rockford, Illinois). An aliquot of 10 g of protein from
ach sample was electrophoresed on a 7.5% SDS-
olyacrylamide gel. Proteins were subsequently transferred
o polyvinylidine difluoride membrane (Immobilon-P
embrane, Millipore, Bedford, Massachusetts) electro-
horetically (100 V for 1 h) and membranes were incubated
ith antibody. The antibodies used in this study were rabbit
nti-phosphorylated ezrin/radixin/moesin (ERM) family,
otal ERM. The antibody against phosphorylated ERM
ecognizes human moesin (phosphorylated at Thr558),
hich also binds to the phosphorylated ezrin (Thr567) and
adixin (Thr564). Therefore, we used the extent of phos-
horylation of ERM as a marker of Rho-kinase activity.
he levels of Western blot for phosphorylated ERM were
ormalized to those for total ERM as a control. Membranes
ere then incubated with a horseradish peroxidase-
onjugated horse anti-rabbit immunoglobulin G antibody
1:5,000). Immunoreactivity was detected by enhanced
hemiluminescence autoradiography (ECL Western blot-
ing detection kit; Amersham Pharmacia Biotechnology,
nited Kingdom).
The obtained samples were washed with ice-cold Tris-
Cl buffer (pH 7.4), mixed with the sample buffer (4%
odium lauryl sulfate, 12% beta-mercaptoethanol, and 20%
lycerol in 100 mM Tris-HCl [pH 6.8]), sonicated (1 min),
oiled (3 min), and finally centrifuged (10,000 g, 60 min,
°C). The resultant supernatant was stored at 80°C until
se. The separation of proteins was carried out according to
he previous study (18), with a minor modification. The
elative intensity of immunoreactive bands was quantified by
mage Master 1D Elite software (Amersham Biotech,
uckinghamshire, United Kingdom), and the data were
stimated as percentage of each control.
xperimental protocols. After the surgical procedure and
nstrumentation, at least 30 min were allowed for stabiliza-
ion while hemodynamic variables were monitored. The
ollowing protocols were examined.
. We infused graded doses of hydroxyfasudil (10, 30, and
100 g/kg, IC), and coronary vascular responses were
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diameters and flows of the LAD.
. The arteriolar vasoconstrictor response to serotonin
before and after hydroxyfasudil (100 g/kg, IC) was
examined with or without inhibition of NO synthase
(L-NMMA, 2 mol/min for 20 min, IC) (Fig. 1).
Hydroxyfasudil or L-NMMA was administered at 5
min before infusion of serotonin. The time interval
between L-NMMA and hydroxyfasudil was also 5 min.
. The arteriolar vasodilator responses to endothelium-
dependent (acetylcholine, 1 g/kg IC) and -independent
(papaverine, 1 mg IC) vasodilators were examined before
and after coronary I (90 min)/R (60 min) under the
following four conditions separately in different animals:
1) control conditions, 2) L-NMMA alone, 3) hydroxyfa-
sudil alone (100 g/kg IC), and 4) hydroxyfasudil plus
L-NMMA (Fig. 1). The time interval between each
treatment was also 5 min. The basal coronary diameter is
before administration of acetylcholine or papaverine either
igure 2. Coronary vasodilator effects of hydroxyfasudil in dogs in vivo. H
igure 1. Experimental protocol. S  serotonin; L  L-NMMA; HF
cclusion.ose-dependent manner, under normal conditions in both small arteries (a) and
nd 7/4 in arterioles, respectively. Hydroxyfasudil also increased coronary bloodbefore or after I/R. Hydroxyfasudil and L-NMMA were
administered at 5 min after administration of acetylcholine
or papaverine. Microspheres were administered at 85 min
after the onset of coronary occlusion.
. After 5 h of reperfusion, LAD and the left circumflex
artery (LCX) and myocardial tissue of LAD and LCX
area were obtained for Western blotting. We reoccluded
the LAD and injected Evans blue dye into a systemic
vein. Then myocardial slices (5 mm) were incubated in
1% 2,3,5-triphenyltetrazolium chloride (Sigma, Japan)
solution to detect the infarct area. Infarct size was
expressed as percentage of the infarct area that was
contiguous with area at risk (19).
rugs. We used the following drugs: hydroxyfasudil
Asahi Kasei Pharma, Tokyo, Japan), acetylcholine
Daiichi-Seiyaku, Tokyo, Japan), papaverine (Dainihon-
eiyaku, Tokyo, Japan), and NG-methyl-L-arginine (L-
xyfasudil (10, 30, and 100 g/kg, IC) caused coronary vasodilation, in a
ydroxyfasudil; Ach  acetylcholine; P  papaverine; Occl  coronaryydro
arterioles (b). Number of vessels per animal used was 5/3 in small arteries
flow (CBF) in a dose-dependent manner (c). *p  0.05.
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aline immediately before use.
tatistical analysis. Results are expressed as means SEM.
ascular responses (Figs. 2a to 2c, 3c, 4c, 6c, 7a to 7c, 8a) were
nalyzed by one-way analysis of variance followed by Scheffe’s
ost-hoc test for multiple comparisons. Difference in the effects
f serotonin, acetylcholine, and papaverine on subepicardial
icrovessels before and after I/R (Figs. 3a, 3b, 4a, 4b, 5a to 5d,
a, and 6b), and difference between infarct size/risk area and
ransmural collateral flow with or without hydroxyfasudil (Fig.
b) were examined by a multiple regression analysis using a
odel in which the change in coronary diameter was set as a
ependent variable (y) and vascular size as an explanatory
ariable (x) while the statuses of hydroxyfasudil and hydroxy-
asudil plus L-NMMA were set as dummy variables (D1, D2)
n the following equation; y a0 a1x a2D1 a3D2, where
0 through a3 are partial regression coefficients. The criterion
or statistical significance was at p  0.05.
igure 3. Effects of hydroxyfasudil on serotonin-induced coronary vascul
asoconstriction of small arteries to vasodilation (a) and significantly enhan
ttenuated the serotonin-induced vasodilation, which was counteracted by
F  S, 13/4 for L  HF  S. *p  0.05, **p  0.01. S  serotonin;
igure 4. Endothelium-dependent coronary vasodilation before and afte
ignificantly impaired coronary vasodilation to acetylcholine under control
ydroxyfasudil (HF) completely preserved the responses. The vasoconstricti
n small arteries. Hydroxyfasudil also prevented the decrease in coronary bl
f vessels per animals used was 7/6 for control (mean diameter 120  7 
nd 5/4 for hydroxyfasudil plus L-NMMA (125  9 m) in small arterie
ydroxyfasudil (68 7 m), and 11/6 for hydroxyfasudil plus L-NMMA (71
 after acetylcholine. *p  0.05; **p  0.01.ESULTS
oronary vasodilator effects of hydroxyfasudil. Intra-
oronary administration of hydroxyfasudil caused a signifi-
ant coronary vasodilation of both small arteries and arte-
ioles (Figs. 2a and 2b, both p  0.05, 10 g/kg vs. 30 and
00 g/kg) in a dose-dependent manner under control
onditions with a resultant increase in CBF (Fig. 2c, p 
.05, C vs. 10, 30 and 100 g/kg). Intracoronary hydroxy-
asudil did not significantly alter mean aortic pressure or
eart rate (Table 1).
emodynamics and blood gases during I/R injury. In
ach experimental condition, mean aortic pressure and heart
ate at baseline were constant and comparable (Table 1), and
xygen partial pressure (PO2), carbon dioxide partial pres-
ure (PCO2), and pH were maintained within the physio-
ogic ranges (pH 7.35 to 7.45, PCO2 25 to 40 mm Hg, PO2
70 mm Hg) throughout the experiments. Hemodynamic
ponses in dogs in vivo. Hydroxyfasudil converted the serotonin-induced
e serotonin-induced vasodilation of arterioles (b). L-NMMA significantly
xyfasudil. Number of vessels per animal used was 18/6 for S, L  S and
-NMMA; HF  hydroxyfasudil; B  before drug; A  after drug.
onary ischemia/reperfusion (I/R) injury in dogs in vivo. Coronary I/R
tions (C) and L-NMMA (L) further suppressed the vasodilation, whereas
uced by L-NMMA after I/R was significantly improved by hydroxyfasudil
ow (CBF) after I/R, which effect was attenuated by L-NMMA. Number
/4 for L-NMMA (123  8 m), 6/4 for hydroxyfasudil (118  8 m),
12/6 for control (70  6 m), 8/4 for L-NMMA (69  7 m), 8/5 forar res
ced th
hydror cor
condi
on ind
ood fl
m), 5
s, and5 m) in arterioles. I/R ischemia/reperfusion; B before acetylcholine;
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February 15, 2005:599–607 Rho-Kinase and Reperfusion Injuryariables at baseline did not significantly change after I/R
ompared with those before I/R (Table 1).
ffects of Rho-kinase inhibition on serotonin-induced
oronary responses. Intracoronary administration of sero-
onin caused coronary vasoconstriction of small arteries and
igure 5. Coronary microvascular responses to acetylcholine before and
fter coronary ischemia/reperfusion (I/R) injury in dogs in vivo. Under
ontrol conditions, I/R significantly impaired coronary vasodilator response
o acetylcholine (a), whereas hydroxyfasudil completely preserved the
esponses in the absence (c) or presence of L-NMMA (d) compared with
hat in the presence of L-NMMA alone (b). Number of vessels per animals
sed was 19/7 under control conditions (before I/R: y  0.3x  35.9, r
0.85; after I/R: y  0.2x  18.1, r  0.80), 13/4 for L-NMMA alone
before I/R: y  0.2x  35.1, r  0.76; after I/R: y  0.2x  12.2, r
0.88), 14/7 for hydroxyfasudil (before I/R: y  0.2x  27.9, r  0.73;
fter I/R: y  0.2x  27.4, r  0.80), and 16/7 for hydroxyfasudil plus
-NMMA (before I/R: y  0.2x  31.8, r  0.83; after I/R: y  0.2x
19.2, r  0.86). **p  0.01. Open circles  before I/R; solid circles 
fter I/R.
igure 6. Endothelium-independent coronary vasodilation before and after
as comparable under all conditions in both small arteries and arterioles. N
m), 5/4 for L-NMMA (123 8 m), 6/4 for hydroxyfasudil (118 8 
nd 12/6 for control (70  6 m), 8/4 for L-NMMA (69  7 m), 8/5 for h
71  5 m) in arterioles. C  control; L  L-NMMA; HF  hydroxyfasudil.asodilation of arterioles under control conditions (Figs. 3a
nd 3b, both p  0.01 vs. basal coronary diameter).
ntracoronary administration of L-NMMA enhanced the
erotonin-induced vasoconstriction and abolished the
erotonin-induced vasodilation of arterioles (Fig. 3b, p 
.01 vs. serotonin, S). By contrast, hydroxyfasudil reversed
he serotonin-induced vasoconstriction of small arteries to
asodilation while it further enhanced the serotonin-
nduced vasodilation of arterioles (Figs. 3a and 3b, both p
.01). The vasodilator effect of hydroxyfasudil on the
oronary response to serotonin was significantly attenuated
y L-NMMA in both-sized arteries (Figs. 3a and 3b, both
 0.01). As a result, serotonin-induced increase in CBF
Fig. 3c) was significantly inhibited by L-NMMA (p 
.05) and enhanced by hydroxyfasudil (p  0.05), the effect
f which was significantly attenuated by L-NMMA (p 
.01).
ndothelium-dependent coronary vasodilation before
nd after I/R. Under control conditions (before I/R),
ntracoronary administration of acetylcholine caused a sig-
ificant coronary vasodilation to a greater extent in arterioles
han in small arteries (Figs. 4a, 4b, and 5a, p  0.01).
oronary I/R significantly impaired the coronary vasodila-
ion to acetylcholine in both sized arteries (both p  0.01)
nd L-NMMA further reduced the vasodilation (Figs. 4a,
b, and 5b both p  0.01), whereas hydroxyfasudil com-
letely preserved (small artery p  0.05, arteriole p  0.01)
he acetylcholine-induced coronary vasodilator response af-
er I/R (Figs. 4a and 4b). The vasoconstriction by
-NMMAwas significantly attenuated by hydroxyfasudil in
oth sized arteries (both p  0.05) with decrement of CBF
Figs. 4a to 4c). When the coronary vasodilator response to
cetylcholine was expressed as a function of basal coronary
iameter, hydroxyfasudil preserved the response after I/R
njury at all sized coronary arteries either in the absence
ary I/R injury in dogs in vivo. Coronary vasodilator response to papaverine
er of vessels per animals used was 7/6 for control (mean diameter 120 
and 5/4 for hydroxyfasudil plus L-NMMA (125 9 m) in small arteries;coron
umb
m),ydroxyfasudil (68  7 m), and 11/6 for hydroxyfasudil plus L-NMMA
I/R  ischemia/reperfusion. B  before papaverine; A  after papaverine.
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Rho-Kinase and Reperfusion Injury February 15, 2005:599–607Figs. 4a, 4b, and 5c, df 2, 25, p  0.01) or presence (Figs.
a, 4b, and 5d, df 2, 24, p  0.01) of L-NMMA compared
ith that in the presence of L-NMMA alone (Figs. 4a, 4b,
nd 5b).
ndothelium-independent coronary vasodilation. Coro-
ary vasodilator response to papaverine was comparable
nder all conditions in both small arteries and arterioles
Figs. 6a and 6b). Similarly, the increase in CBF to
apaverine (Fig. 6c) was also comparable under all condi-
ions in both-sized arteries. Those coronary vasodilator
esponses were resistant to the blockade of NO synthesis
ith L-NMMA (Figs. 6a and 6b).
ctivation of Rho-kinase by ischemia-reperfusion causes
own-regulation of eNOS protein expression. Rho-
inase activity after a 90-min period of ischemia was
ignificantly greater in the ischemic LAD than in the
onischemic LCX in the control group (Fig. 7a, p  0.01).
his Rho-kinase activation was significantly suppressed by
ydroxyfasudil in the ischemic LAD (Fig. 7a, p  0.01).
xpression of eNOS protein in the ischemic endocardium
f the LAD area (as determined by Western blotting) was
ignificantly decreased (79  4%, p  0.05) compared with
he nonischemic endocardium of the LCX area (100 7%),
hich was also improved by hydroxyfasudil (105  6%)
Fig. 7b, p  0.05). There was no significant difference in
he eNOS expression in the epicardium between the LAD
nd LCX area (Fig. 7c).
ffect of Rho-kinase inhibition on I/R-induced myocar-
ial infarct size. Ischemia-reperfusion injury caused myo-
ardial infarct area that was approximately 50% of the left
entricular risk area, and intracoronary L-NMMA did not
urther increase the I/R-induced infarction size (Fig. 8a).
ntracoronary pretreatment with hydroxyfasudil markedly
educed the infarct size (p  0.01 vs. control), and this
eneficial effect of hydroxyfasudil was significantly attenu-
ted by L-NMMA (Fig. 8a p 0.01). In the control group,
igure 7. Western blotting showing the effects of hydroxyfasudil (HF) on R
nd LCX. (a) Rho-kinase activity in coronary artery; (b) expression of eN
ho-kinase activity was determined by the degree of ezrin-radixin-moesin p
as completely inhibited by cotreatment with hydroxyfasudil. Expression
ecreased compared with the non-ischemic endocardium of LCX area, where was an inverse relation between the infarct area and Rollateral blood flow measured by microsphere technique (r
0.93, p  0.01), and hydroxyfasudil significantly shifted
he regression line downward as compared with the control
roup (p  0.01), that is, smaller infarct size for a given
ollateral flow (Fig. 8b).
ISCUSSION
he major findings of the present in vivo study in the canine
oronary microcirculation were that: 1) a specific Rho-
inase inhibitor hydroxyfasudil preserved the endothelium-
ependent coronary vasodilator responses after coronary I/R
njury, 2) hydroxyfasudil also reduced myocardial infarct
ize, and 3) NO may be involved in those cardiovascular
rotective effects of hydroxyfasudil. To the best of our
nowledge, this is the first report that demonstrates the
sefulness of a Rho-kinase inhibitor to prevent coronary I/R
njury in vivo.
alidations of experimental model and methodology. On
he basis of the previous reports (4,12,20), we chose the
dequate dose of hydroxyfasudil, acetylcholine, papaverine,
nd L-NMMA to examine the effects of the Rho-kinase
nhibition, endothelium-dependent and -independent vaso-
ilator responses, and inhibition of NO synthesis on coro-
ary vascular responses before and after coronary I/R,
espectively. The methodologic validity of the present study
as been confirmed previously (15). After 60 to 90 min of
schemia, ultrastructural damage of coronary endothelium
as observed particularly in the subendocardium in the
resent study, a consistent finding to the previous study
21).
ydroxyfasudil as a specific Rho-kinase inhibitor in the
oronary microcirculation in vivo. Shimokawa et al. (11)
ave recently demonstrated that hydroxyfasudil is a specific
ho-kinase inhibitor that markedly inhibits coronary vasospas-
ic responses in a porcine model; its inhibitory effect on
inase activity and on eNOS protein expression in the myocardium of LAD
protein in endocardium; (c) expression of eNOS protein in epicardium.
horylation (p-ERM/t-ERM). Rho-kinase activation in the ischemic LAD
OS protein in the ischemic endocardium of LAD area was significantly
as again improved by hydroxyfasudil. *p  0.05, **p  0.01.ho-k
OS
hosp
of eNho-kinase is 100 times greater than on protein kinase C and
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February 15, 2005:599–607 Rho-Kinase and Reperfusion Injury,000 times greater on myosin light-chain kinase. Hydroxyfa-
udil has potent vasodilator effects on coronary arteries through
nhibition of Rho-kinase-mediated phosphorylations of myo-
in light chains (11). In the present study, intracoronary
ydroxyfasudil caused coronary microvascular vasodilation in a
ose-dependent manner in vivo, and its vasodilator effect was
reater in arterioles than in small arteries (Fig. 2). Hydroxyfa-
udil suppressed the serotonin-induced vasoconstriction of
mall arteries, whereas it enhanced the serotonin-induced
asodilation of arterioles in vivo (Fig. 3). This finding is in
ccordance with the hypothesis that the calcium sensitization
f vascular smooth-muscle cells mediated by Rho-kinase plays
key role in the molecular mechanisms of coronary hypercon-
triction (12). Furthermore, in the present study, intracoronary
igure 8. (a) Ischemia/reperfusion (I/R)-induced LV infarct size in dogs in
ivo. Hydroxyfasudil significantly reduced the I/R-induced LV infarct size.
he beneficial effect of hydroxyfasudil was partially attenuated by L-NMMA,
hile L-NMMA alone did not significantly increase the infarct size. Number
f animals used was each 7 for C, HF, and LHF, and 4 for L. C control;
 L-NMMA; HF  hydroxyfasudil. **p  0.01. (b) Plot of infarct size
xpressed as a percentage of the risk area and regional collateral flow during
schemia. In the control group, there was an inverse relation between infarct
rea and collateral flow measured by microsphere (r  0.93, p  0.01), and
ydroxyfasudil significantly shifted the regression line downward as compared
ith the control group (p 0.01). Number of animals used was five for control
onditions and four for hydroxyfasudil.-NMMA significantly attenuated serotonin-induced coro- eary vasodilator responses, which were improved by hydroxy-
asudil, indicating an involvement of NO-mediated mecha-
ism in the beneficial effects of the Rho-kinase inhibitor.
amping et al. (22) demonstrated that coronary vascular
esponse to serotonin is determined by a balance between
-HT1 receptor-mediated dilatation of coronary arterioles and
-HT2 receptor-mediated vasoconstriction of small coronary
rteries. Inhibition of NO synthase enhances coronary vaso-
onstriction to serotonin in both-sized arteries. Our present
esults are in agreement with those of Lamping et al. The
eneficial vasodilator effect of hydroxyfasudil on coronary
ascular response to serotonin is mediated by its action on both
ascular smooth muscle and the endothelium as shown in
igure 3. Thus, it is possible that the beneficial effect of
ho-kinase blockade with hydroxyfasudil is mediated by its
ction on both vascular smooth muscle and the endothelium
22). Serotonin released by aggregating platelets has been
mplicated for coronary vasospasm in the presence of damaged
ascular endothelium (5,23).
eneficial effects of a Rho-kinase inhibitor on coronary
/R injury. In the present study, hydroxyfasudil exerted
eneficial effects on I/R-induced endothelial injury in the
anine coronary microcirculation in vivo through the NO-
ependent mechanism (Figs. 4 and 5). This dose of hy-
roxyfasudil (100 g/kg) selectively inhibits Rho-kinase
ctivity and effectively prevents serotonin-induced coronary
yperconstriction. Recent studies have demonstrated that
GMP-dependent protein kinase inhibits RhoA phosphor-
lation by inhibiting the membrane binding of RhoA, in
hich the NO-mediated mechanism may inhibit the
hoA/Rho-kinase pathway (24–26). It was previously
emonstrated that statins attenuate I/R injury of the heart
nd the brain in rats and mice, demonstrating the Rho-
ediated and NO-dependent protective effect of statins
27,28). Hydroxyfasudil also inhibits the production of
uperoxide anions in neutrophils (29) and various
hemoattractant-induced migration of those cells (14) in a
anine model of cerebral ischemia. Furthermore, treatment
ith hydroxyfasudil in human saphenous vein endothelial
ells reversed the hypoxia-induced decrease in eNOS
ctivity as examined by the citrulline conversion assay and
,5-diaminofluorescein diacetate fluorescence method
13). In the present study, I/R increased Rho-kinase
ctivity, and hydroxyfasudil significantly inhibited the
ho-kinase activation. These findings suggest that NO is
nvolved in the protective effect of hydroxyfasudil with an
ncrease in eNOS activity and a decrease in Rho-kinase
ctivity during reperfusion injury.
In the present study, the vasodilator effects of hydroxy-
asudil were significantly attenuated by L-NMMA (Figs. 3
nd 4). The eNOS expression was decreased in the ischemic
rea of the endocardium compared with that of the epicar-
ium under control conditions, which was improved by
ydroxyfasudil (Fig. 7). We have previously demonstrated
hat endocardial arteriolar dilation during reactive hyper-
mia is more sensitive to L-NMMA than epicardial arte-
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Rho-Kinase and Reperfusion Injury February 15, 2005:599–607iolar dilation (30). These findings indicate that the perfu-
ion of the endocardium is more dependent on NO than
hat of the epicardium and that endothelial damage after
/R in arterioles may be greater in the endocardium than in
he epicardium.
In the present study, hydroxyfasudil exerted cardiovascu-
ar protective effects on coronary I/R injury, as did precon-
itioning (31,32). However, the mechanism by which hy-
roxyfasudil and preconditioning protect coronary I/R
njury appears to be different. Endogenous NO does not
lter the infarct size after I/R and is not involved in the
rotective mechanism of preconditioning in pigs or rabbits
33,34). It has been suggested that preconditioning pre-
erves myocardial creatine phosphate and intracellular pH
35). Furthermore, ischemic preconditioning increases
denosine production and activates protein kinase C, which
lso enhances adenosine production during I/R injury.
In the present study, hydroxyfasudil significantly reduced
yocardial infarct size with increment of coronary collateral
lood flow, at least in part, thorough the NO-mediated
echanism (Fig. 8). Shimokawa et al. (11) demonstrated
hat hydroxyfasudil inhibits both MLC mono- and diphos-
horylations. Satoh et al. (14) showed that hydroxyfasudil
lso protects the brain from ischemic injury through inhi-
ition of superoxide production and neutrophil infiltration.
ohri et al. (36) demonstrated that fasudil suppresses
oronary microvascular spasm in patients with microvascular
ngina. Wolfrum et al. (37) recently demonstrated that
nhibiting Rho-kinase has cardioprotective effects to reduce
nfarct size by activating phosphatidylinositol 3-kinase/
rotein kinase Akt/eNOS pathways. All these mechanisms
ay be involved in the beneficial effects of hydroxyfasudil on
he I/R-induced myocardial injury.
Hydroxyfasudil increases blood supply to the ischemic
egion of the myocardium and prevents I/R-induced myo-
ardial injury. Furthermore, it has been recently demon-
trated that an estrogen receptor modulator, raloxifene, also
educes I/R-induced myocardial infarct size, whereas an
nhibitor of NO synthesis (L-NAME) or a blocker of
alcium-activated K channels (charybdotoxin) partly at-
able 1. Hemodynamics During Myocardial Ischemia-Reperfusio
n Baseline
BP (mm Hg)
Control 7 91  4
L-NMMA 4 88  8
Hydroxyfasudil 7 92  9
L-NMMA  hydroxyfasudil 7 89  6
eart rate (beats/min)
Control 7 151  5
L-NMMA 4 147  7
Hydroxyfasudil 7 152  7
L-NMMA  hydroxyfasudil 7 151  6
esults are expressed as mean  SEM.
ACh  acetylcholine; I/R  ischemia/reperfusion; MBP  mean blood pressureenuates the effect of raloxifene (19). These results suggesthat cardioprotective effects of those inhibitors may be
ediated in part by the compensatory effects of NO and
ndothelium-derived hyperpolarizing factor (20). Several
tudies using NO synthase inhibitors (38,39) or eNOS-
eficient mice (40) demonstrated an increase in infarct size
fter I/R. The effect of NO synthesis inhibition on the
nfarct size might be species- and dose-dependent.
linical implications and conclusions. The present study
as demonstrated for the first time that hydroxyfasudil, a
pecific Rho-kinase inhibitor, has NO-dependent cardio-
ascular protective effects on coronary I/R injury in vivo.
ho-kinase inhibitor has also an antianginal effect in a
anine model of angina (41), patients with effort angina
42), and those with vasospastic angina (43). Moreover, it
as been recently reported that hydroxyfasudil may be
ffective for the treatment of pulmonary hypertension (44).
ndeed, Rho-kinase inhibitors may be useful for the treat-
ent of a wide range of cardiovascular diseases (10). The
resent study suggests that Rho-kinase inhibitors may also
e useful for the treatment of coronary I/R injury in
umans.
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